URGN ▲ +1.2% - UroGen Pharma Ltd.
$URGN - UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer
28-OCT-2026 08:00 AM ET
Share this post
More filings for $URGN
URGN - UroGen Pharma Ltd. - SEC Filing Update (27-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 27, 2026URGN ▼ -0.4% - UroGen Pharma Ltd.Oct 27, 2026URGN ▼ -0.6% - UroGen Pharma Ltd.Sep 2, 2026URGN - UroGen Pharma Ltd. - SEC Filing Update (12-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 12, 2026
View full $URGN filing history →💬 Comments
Loading comments…
Leave a comment